Key indicators: single-crystal X-ray study; T = 100 K; mean (C-C) = 0.003 Å; R factor = 0.064; wR factor = 0.216; data-to-parameter ratio = 28.5.
Related literature
For background to the prevalence of epilepsy and epilepsy drugs, see: Sander & Shorvon (1987) ; Saxena & Saxena (1995) ; Edafiogho & Scott (1996) . For the use of aryl semicarbazones as anti-convulsants, see: Aboul-Enein et al. (2012) ; Dimmock et al. (1993 Dimmock et al. ( , 1995 . For a related structure, see: Attia et al. Refinement R[F 2 > 2(F 2 )] = 0.064 wR(F 2 ) = 0.216 S = 0.98 7494 reflections 263 parameters H atoms treated by a mixture of independent and constrained refinement Á max = 0.31 e Å À3 Á min = À0.32 e Å À3 Table 1 Hydrogen-bond geometry (Å , ).
Cg2 and Cg3 are the centroids of the C1-C6 and C10-C15 benzene rings, respectively. Symmetry codes: (i) Àx þ 1; Ày þ 1; Àz þ 1; (ii) Àx þ 2; y þ 1 2 ; Àz þ 3 2 ; (iii) Àx þ 2; Ày þ 1; Àz þ 2; (iv) Àx þ 2; Ày þ 1; Àz þ 1.
Data collection: CrysAlis PRO (Agilent, 2011); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: ORTEP-3 (Farrugia, 1997) and DIAMOND (Brandenburg, 2006) ; software used to prepare material for publication: publCIF (Westrip, 2010) . 
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Comment
Epilepsy is one of the most widespread pathologies of the human brain, affecting approximately 1% of world population (Sander & Shorvon, 1987) . Current anti-epileptic drugs suffer from a number of disadvantages including the fact that approximately one quarter of epileptic patients have seizures that are resistant to the available medical therapy (Saxena & Saxena, 1995) . Additionally, many clinically used anti-epileptic drugs cause significant side-effects which may limit their usefulness (Edafiogho & Scott, 1996) . Accordingly, the evolution of novel anti-convulsants is a continuing challenge. An evaluation of the literature revealed that aryl semicarbazones were found to exhibit significant anti-convulsant activities Dimmock et al., 1995; Dimmock et al., 1993) . The novel title compound, namely (2E)-2-[3-(1H-imidazol-1-yl)-1-(4-methoxphenyl)propylidene]-N-(2-methylphenyl)hydrazinecarboxamide (I) will be evaluated as anti-convulsant in experimental animal models. Herein, we describe the results of its crystal structure determination.
In (I), Fig. 1 , the conformation about the N3═C9 bond [1.287 (3) Å] is E. The dihedral angles between the imidazolyl ring and the methoxy-and methyl-benzene rings are 49.42 (13) and 42.62 (13)°, respectively; the dihedral angle between the benzene rings is 20.11 (11)°. Despite these angles of inclination, overall the molecule as a disk which contrasts the flat topology in the non-methoxy species . The methoxy group is co-planar with the benzene ring to which it is attached as seen in the value of the C16-O2-C13-C12 torsion angle of -173.1 (2)°. Within the urea moiety, the N -H atoms are anti to each other and the N1-H forms an intramolecular N-H···N hydrogen bond to define a S(5) loop, Table 1 .
In the crystal structure, centrosymmetric dimers are formed via N-H···N(imidazolyl) hydrogen bonds and 18membered {···HNNC 3 NCN} 2 synthons, Fig. 2 and Table 1 . These aggregates are connected into a three-dimensional architecture by C-H···O(carbonyl) and (methylene)C-H···π interactions, Fig. 3 and Table 1 .
Experimental
Acetic acid (2 drops) was added to a stirred solution of 3-(1H-imidazol-1-yl)-1-(4-methoxyphenyl)propan-1-one (0.23 g, 1 mmol) and N-(2-methylphenyl)hydrazinecarboxamide (0.17 g, 1 mmol) in absolute ethanol (10 ml). The reaction mixture was stirred at room temperature for 18 h. The solvent was concentrated under reduced pressure and the 
Refinement
Carbon-bound H-atoms were placed in calculated positions [C-H = 0.95 to 0.99 Å, U iso (H) = 1.2-1.5U eq (C)] and were included in the refinement in the riding model approximation. The amino H-atoms were refined freely. The crystal studied was a non-merohedral twin with the minor component being 48.3 (1)%. The (6 9 0) reflection was omitted owing to poor agreement.
Computing details
Data collection: CrysAlis PRO (Agilent, 2011); cell refinement: CrysAlis PRO (Agilent, 2011); data reduction: CrysAlis PRO (Agilent, 2011); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: ORTEP-3 (Farrugia, 1997) and DIAMOND (Brandenburg, 2006) ; software used to prepare material for publication: publCIF (Westrip, 2010) .
Figure 1
The molecular structure of (I) showing the atom-labelling scheme and displacement ellipsoids at the 50% probability level. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
1-{(E)-[3-(1H-Imidazol-1-yl)-1-(4-methoxyphenyl)propylidene]amino}-3-(2-methylphenyl)urea
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq O1 0.84974 (15) 0.35509 (7) 0.8918 (2) 0.0223 (4) Symmetry codes: (i) −x+1, −y+1, −z+1; (ii) −x+2, y+1/2, −z+3/2; (iii) −x+2, −y+1, −z+2; (iv) −x+2, −y+1, −z+1.
